A recent Capitol Hill briefing hosted by IDSA provided clinician, industry, and patient perspectives on antimicrobial resistance and the need for new incentives for research and development for new antibiotics, antifungals and rapid diagnostics. The event featured presentations from IDSA Past President, Barbara Murray, MD, FIDSA, and Christine Ginocchio, MD, of bioMérieux. House sponsors of the Reinventing Antibiotic and Diagnostic Innovation (READI) Act
, Reps. Charles Boustany (R-LA), a former surgeon, and Mike Thompson (D-CA) also addressed attendees. Additionally, Dr. Murray met with key congressional staffers to encourage support for the bill.
Roughly 150 IDSA members joined the effort by emailing their representatives in support of the READI Act, which would create a tax credit to support clinical trials of new drugs and diagnostics that target serious or life-threatening infections and address an unmet medical need. You can still support passage of the READI Act by taking 3 minutes on the IDSA Action Center
to complete the latest action alert.